Substance P and Chronic Pain in Patients with Chronic Inflammation of Connective Tissue

Barbara Lisowska, Aleksander Lisowski, Katarzyna Siewruk, Barbara Lisowska, Aleksander Lisowski, Katarzyna Siewruk

Abstract

Objective: Evidence suggests that substance P (SP) is involved in chronic joint inflammation, such as the pathogenesis of rheumatoid arthritis and osteoarthritis. The goal of the research was to evaluate the correlation between chronic pain and changes in the SP level in patients with chronic inflammation of the connective tissue.

Methods: Patients with osteoarthritis and rheumatoid arthritis were enrolled in this study. The relationship between chronic pain intensity and the serum SP concentration was evaluated in these groups of patients with osteoarthritis and rheumatoid arthritis.

Results: The results showed a positive correlation between the serum SP concentrations and chronic pain intensity.

Conclusions: 1. The SP serum concentration was significantly different between the groups of patients with OA and RA. 2. There was a positive correlation between the serum SP concentration and chronic pain intensity in OA and RA patients.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. The relationship between NPS and…
Fig 1. The relationship between NPS and the serum concentration of substance P (SP) for OA patients.
Fig 2. Interaction between the serum concentration…
Fig 2. Interaction between the serum concentration of substance P (SP) and the disease activity (DAS) and intensity of pain (NPS) for patients with RA.

References

    1. O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004; 201: 167–180.
    1. Pezet S, Malcangio M, McMahon SB. BDNF: a neuromodulator in nociceptive pathways? Brain Res Brain Res Rev 2002; 40: 240–249.
    1. Zhang Y, Berger A, Milne CD, Paige CJ. Tachykinins in the immune system. Curr Drug Targets 2006; 7: 1011–1020.
    1. Lisowska B. Role and significance of substance P. Geriatria Polska 2007; 3: 63–67.
    1. Goto T, Tanaka T. Tachykinins and tachykinin receptors in bone. Microsc Res Tech 2002; 58: 91–97.
    1. O'Shaughnessy MC, Vetsika EK, Inglis JJ, et al. The effect of substance P on nitric oxide release in a rheumatoid arthritis model. Inflamm Res 2006; 55: 236–240.
    1. Keeble JE, Brain SD. A role for substance P in arthritis? Neurosci Lett 2004; 361: 176–179.
    1. Saxler G, Löer F, von Knoch M, et al. von Knoch F, Hanesch U. [Localization of the neurokinin 1 receptor in hip joints of patients with painful osteoarthritis]. Z Orthop Ihre Grenzgeb 2005; 143: 424–430.
    1. Saxler G, Löer F, Skumavc M, Pförtner J, Hanesch U. Localization of SP- and CGRP-immunopositive nerve fibers in the hip joint of patients with painful osteoarthritis and of patients with painless failed total hip arthroplasties. Eur J Pain 2007; 11:67–74.
    1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31:315–324.
    1. Grimsholm O, Rantapää-Dahlqvist S, Forsgren S. Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R416–R426.
    1. O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004; 201: 167–180.
    1. Baerwald C, Burmester G, Krause A. Interactions of autonomic nervous, neuroendocrine, and immune systems in rheumatoid arthritis. Rheum Dis Clin North Am 2000; 26: 841–857.
    1. Lambert N, Lescoulié PL, Yassine-Diab B, Enault G, Mazières B, De Préval C, et al. Substance P enhances cytokine-induced vascular cell adhesion molecule–1 (VCAM–1) expression on cultured rheumatoid fibroblast-like synoviocytes. Clin Exp Immunol 1998; 113: 269–275.
    1. Khan MM, Douglas SD, Benton TD. Substance P-neurokinin–1 receptor interaction upregulates monocyte tissue factor. J Neuroimmunol 2012; 242: 1–8. 10.1016/j.jneuroim.2011.10.012
    1. Hernanz A, Medina S, de Miguel E, Martín-Mola E. Effect of calcitonin gene-related peptide, neuropeptide Y, substance P, and vasoactive intestinal peptide on interleukin-1beta, interleukin–6 and tumor necrosis factor-alpha production by peripheral whole blood cells from rheumatoid arthritis and osteoarthritis patients. Regul Pept 2003. 15; 115:19–24.
    1. Hernanz A, De Miguel E, Romera N, Perez-Ayala C, Gijon J, Arnalich F. Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheumatol 1993; 32: 31–35.
    1. Marshall KW, Chiu B, Inman RD. Substance P and arthritis: analysis of plasma and synovial fluid levels. Arthritis Rheum 1990; 33: 87–90.
    1. Lotz M, Carson DA, Vaughan JH. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 1987; 235: 893–895.
    1. Partsch G, Matucci-Cerinic M, Marabini S, Jantsch S, Pignone A, Cagnoni M. Collagenase synthesis of rheumatoid arthritis synoviocytes: dose-dependent stimulation by substance P and capsaicin. Scand J Rheumatol 1991; 20: 98–103.
    1. Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, Basbaum AI. Intraneuronal substance P contributes to the severity of experimental arthritis. Science 1984; 226: 547–549.
    1. Levine JD, Moskowitz MA, Basbaum AI. The contribution of neurogenic inflammation in experimental arthritis. J Immunol 1985; 135: 843s–847s.
    1. Matucci-Cerini M, Marabini S, Partsch G, Cagnoni M. High levels of substance P in rheumatoid arthritis synovial fluid. Lack of substance P production by synoviocytes in vitro. Clin Exp Rheumatol 1991; 9: 440–441.
    1. Straub RH, Cutolo M. Involvement of the hypothalamic-pituitary-adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arthritis Rheum 2001; 44: 493–507.
    1. Karagiannides I, Stavrakis D, Bakirtzi K, Kokkotou E, Pirtskhalava T, Nayeb-Hashemi H, et al. Substance P (SP)-neurokinin–1 receptor (NK-1R) alters adipose tissue responses to high-fat diet and insulin action. Endocrinology 2011; 152: 2197–2205. 10.1210/en.2010-1345
    1. Rocha VZ, Folco EJ. Inflammatory concepts of obesity. Int J Inflam 2011; 529061 10.4061/2011/529061
    1. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112:1821–1830.
    1. Garip Y, Eser F, Aktekin LA, Bodur H. Fatigue in rheumatoid arthritis: association with severity of pain, disease activity and functional status. Acta Reumatol Port 2011; 36: 364–369.
    1. Eser F, Garip Y, Bodur H. Extra articular manifestations in Turkish patients with rheumatoid arthritis: impact of EAMs on the health-related quality of life in terms of disease activity, functional status, severity of pain, and social and emotional functioning. Rheumatol Int 2012; 32: 1521–1525. 10.1007/s00296-011-1822-1
    1. Basbaum A. Pain physiology: basic science. Can J Anesth 2002; 49: R1.
    1. Weidler C, Holzer C, Harbuz M, Hofbauer R, Angele P, Schölmerich J, et al. Low density of sympathetic nerve fibers and increased density of brain derived neurotrophic factor positive cells in RA synovium. Ann Rheum Dis 2005; 64: 13–20.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera